Trials / Recruiting
RecruitingNCT06643741
Non-Invasive Preeclampsia Screening and Biobank
Collection of Pregnancy Outcome Data and Whole Blood Samples From Women Undergoing Non-Invasive Screening for Early, Preterm, and Term Preeclampsia
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,550 (estimated)
- Sponsor
- Sequenom, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
Detailed description
To collect relevant pregnancy outcome data, medical history, and blood samples from pregnant women carrying a singleton fetus undergoing non-invasive screening for early, preterm and term pre-eclampsia (PE) starting at 11 weeks 0 days to 14 weeks 0 days (≥11 - ≤14) gestation in support of validating the Labcorp Preeclampsia ScreenTM assay. Data will be used to examine assay performance and develop new testing methods.
Conditions
Timeline
- Start date
- 2025-02-02
- Primary completion
- 2026-06-01
- Completion
- 2026-07-01
- First posted
- 2024-10-16
- Last updated
- 2026-01-23
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06643741. Inclusion in this directory is not an endorsement.